At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 18 enrolled
Drug / intervention
risankizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Open-Label Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
In Brief
A Phase 3 clinical trial evaluating risankizumab for Psoriasis. Completed, enrolled 18 participants across 9 sites.
Detailed Summary
The purpose of this study is to investigate the safety and efficacy of two different dose regimens of risankizumab for Japanese subjects with generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 2017
Enrollment StartJan 2017
Primary CompletionSep 2017
Study CompletionNov 2020
TodayJul 2026
First PostedJan 16, 2017
Enrollment StartJan 26, 2017
Primary CompletionSep 17, 2017
Study CompletionNov 19, 2020
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 9.5 years ago
Interventions
risankizumabdrug
risankizumab administered by subcutaneous injection